Evidence map›Paper›PMID 31662754›Full record

ArticleJournal of oncology2019

IL-2 Induces Transient Arrest in the G1 Phase to Protect Cervical Cancer Cells from Entering Apoptosis.

María Del Carmen Lagunas-Cruz, Arturo Valle-Mendiola, Jonathan Trejo-Huerta, Leticia Rocha-Zavaleta, María de Lourdes Mora-García, Adriana Gutiérrez-Hoya, Benny Weiss-Steider, Isabel Soto-Cruz

Open access · hybridAbstract read
In one paragraph

Article in Journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

María Del Carmen Lagunas-CruzMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, CP 09230 Mexico City, Mexico.
Arturo Valle-MendiolaMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, CP 09230 Mexico City, Mexico.ORCID https://orcid.org/0000-0001-6782-4547
Jonathan Trejo-HuertaMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, CP 09230 Mexico City, Mexico.
Leticia Rocha-ZavaletaDepartment of Molecular Biology and Biotechnology, Institute of Biomedical Research, National University of Mexico, Mexico City, Mexico.ORCID https://orcid.org/0000-0002-3801-5393
María de Lourdes Mora-GarcíaMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, CP 09230 Mexico City, Mexico.
Adriana Gutiérrez-HoyaMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, CP 09230 Mexico City, Mexico.
Benny Weiss-SteiderMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, CP 09230 Mexico City, Mexico.
Isabel Soto-CruzMolecular Oncology Laboratory, Cell Differentiation and Cancer Research Unit, FES Zaragoza, National University of Mexico, Batalla 5 de Mayo S/n Col. Ejército de Oriente, CP 09230 Mexico City, Mexico.ORCID https://orcid.org/0000-0001-5115-3654
Secretaría de Ciencia, Humanidades, Tecnología e Innovación · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin 2 (IL-2) has been used for the treatment of different types of cancer that express the IL-2 receptor (IL-2R). However, the effect of IL-2 on cervical cancer cells is unknown. IL-2R is present in normal cells of the immune system but not in the healthy cervix. We report that IL-2R is expressed in cervical cancer cells. IL-2 decreases cervical cancer cell proliferation via transient arrest of the G1 phase, which does not result in apoptosis or senescence. IL-2 upregulates the expression of p53 and p21 and downregulates cyclin D. In addition, we report the resistance of cervical cancer cells to treatments that induce apoptosis in HeLa and INBL cells. When arrested cells were treated with cisplatin, the cytokine protected cells from apoptosis induced by cisplatin. The effects of IL-2 on the cell cycle do not induce cellular senescence or activate the proapoptotic protein Bax. The cell arrest induced by IL-2 is conferring protection to cells against apoptosis.

Identifiers

PMID31662754
PMCPMC6791272
OpenAlexW2976485001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.